Persistent low mood, anxiety or loss of interest during menopause deserves assessment. Learn which changes matter and how individualized support is framed.
On October 3, 2026, Premium Medical Circle published Marianne Waldenfels’s article Menopause: When Low Moods Become a Warning Sign, featuring psychologist and psychotherapist Sandra Tschöpe’s account of when persistent mood changes warrant professional support.
In its September 30, 2026 clinical discussion, Psychiatric Times described an approach based on symptom severity. It distinguished subthreshold mood symptoms from severe depression and pointed clinicians toward guideline-based psychotherapy and/or antidepressants for severe depression.
The October reporting does not replace that approach. It challenges the assumption that distress during menopause should simply be accepted as ordinary hormonal fluctuation.
The distinction matters: acknowledging the menopausal transition is not the same as explaining every emotional change through it. The article places persistent symptoms within a broader assessment of mental health and daily life rather than treating menopause as a complete explanation.
That is a more useful starting point than asking whether a woman has had a difficult day. The report separates occasional mood swings from an ongoing change that affects how life feels or how manageable it has become. Neither the presence of sadness alone nor its timing around menopause answers that question.
For a professional conversation, the relevant information is how long the change has lasted and what it is affecting. Work and relationships are part of that picture. So are enjoyment and the energy available for life beyond obligations.
The practical message is to seek assessment when symptoms persist or meaningfully interfere with life. It is not necessary to arrive with a diagnosis or to know whether hormones are involved. Refemina’s broader discussion of midlife mood changes provides context around that distinction.
The October article identifies several experiences worth taking seriously:
The range matters because the concern may be more than sadness. Loss of interest can be the change a woman notices most clearly. For someone else, exhaustion or anxiety may dominate the conversation.
The report’s emphasis is on describing the whole experience rather than choosing a single symptom that appears to fit menopause. Reduced drive and withdrawal belong in that account alongside mood. A clinician needs the wider picture to assess what kind of support is appropriate.
A useful description can remain straightforward: what has changed, how persistent it has become and how it affects ordinary life. There is no need to turn those observations into a self-diagnosis. The purpose of bringing them to a professional is to have their meaning assessed rather than deciding alone which label applies.
This is one of the report’s most relevant points for midlife. An assessment based only on whether someone is still fulfilling obligations can miss the loss of quality of life behind those obligations. The ability to keep going is not the same measure as feeling well.
The article therefore gives room to discuss what remains after work and family responsibilities are met. If enjoyment has faded or personal energy has become depleted, those changes belong in the conversation too. They do not need to be hidden behind the fact that necessary tasks are still getting done.
Its practical advice is not to wait until every responsibility becomes impossible before asking for help. Support can begin with describing the cost of continuing as things are, including the parts of life that have quietly fallen away.
The report names a GP or gynecologist as possible starting points. A mental-health professional or menopause specialist may also be an appropriate person for that first conversation. The aim is professional evaluation rather than a presumption that one route must explain everything.
This keeps the discussion open enough to address both the menopausal transition and other possible contributors. It also avoids making women choose their own explanation before they have been assessed. A concern can be brought to care as persistent low mood or loss of interest without being presented as either a hormone problem or a mental-health diagnosis.
Questions about available support can sit alongside that appointment. Refemina’s guide to building practical and emotional support offers a wider frame for the people and professional relationships around midlife care.
This gives sleep a place in the assessment rather than treating it as a separate concern. In the report’s account, nighttime symptoms and daytime emotional wellbeing can be connected. Discussing both allows the clinician to understand more of the experience being described.
That does not require a woman to decide which problem came first. The useful information is whether sleep has changed and whether mood or anxiety has changed alongside it. Sleep support is among the options discussed in the article’s account of personalized care.
The editorial implication is straightforward: a conversation about low mood should leave room for the night as well as the day. Sleep disruption is relevant context, not a reason to dismiss persistent distress as something that needs no further attention.
The primary article describes several approaches that may form part of an individualized plan:
Sandra Tschöpe’s discussion does not frame support as a choice between hormones and mental-health care. The article describes the possibility of combining approaches. Its focus is matching care to the person rather than selecting a treatment because menopause happens to be part of her life stage.
The Psychiatric Times discussion adds the distinction based on severity. For severe depression, it points toward guideline-based psychotherapy and/or antidepressants. That is a different clinical question from whether sleep support or exercise might contribute to wellbeing.
For readers, the practical next step is a conversation about a personalized plan rather than choosing a treatment from a list. Questions can address which symptoms the plan is intended to help and how life circumstances or existing conditions affect the options. Those decisions belong with qualified professionals who can assess the individual situation.
The evidence presented does not establish that menopause caused an individual woman’s symptoms. An association between the transition and depressive symptoms cannot identify the cause for one person. That boundary is why a broader evaluation remains part of the article’s advice.
Two treatment limits also need to stay clear. Hormone therapy is not a conventional antidepressant or a substitute for appropriate depression care. The reporting does not establish that exercise or strength training treats clinical depression, so movement should be understood as supportive advice rather than replacement treatment.
With those boundaries in place, the practical message remains clear: persistent symptoms and reduced quality of life deserve professional attention. Assessment can begin before the explanation is settled and before outward functioning has broken down.
The direction for clinical practice is earlier recognition of persistent distress, broader assessment and care matched to the person rather than to a hormonal label.
Choosing whether persistent low mood needs assessment comes before choosing a treatment, and Refemina takes on the editorial task of explaining the evidence around that decision. When health content turns distress into another hormone or supplement opportunity, its research-led coverage helps readers separate credible findings from product-led claims while keeping confidence and quality of life within the midlife picture.
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources